生物过程
生物反应器
诱导多能干细胞
巨噬细胞
细胞生物学
再生医学
过程(计算)
造血
免疫系统
计算机科学
生物
干细胞
药物发现
胚胎干细胞
协议(科学)
良好制造规范
组织工程
计算生物学
制造工艺
商业化
细胞疗法
细胞培养
微载波
电池类型
生物技术
纳米技术
生化工程
工艺验证
药物开发
生物信息学
过程开发
细胞
移植
作者
Fawaz Saleh,Edwin Emilio Valdivia Malqui,Ingrid Gensch,Maximilian Schinke,Malene Kappelhøj,Eirini Nikolouli,Ariane Hai Ha Nguyen,M Jang,Débora Basílio-Queirós,Nico Lachmann
标识
DOI:10.1038/s41596-025-01313-x
摘要
Macrophages are crucial in immune responses, tissue repair and homeostasis, making them prime candidates for translational applications. Induced pluripotent stem cell (iPS cell)-derived macrophages hold considerable promise for regenerative medicine, cancer therapy, inflammatory disease treatment and in vitro bioassays. However, cost-effective, standardized intermediate-scale bioreactor systems tailored for early-stage research and drug discovery in academia remain limited. Here, we present an extension of our previously published protocol that is feeder free, semi-defined and user friendly, enabling the standardized production of iPS cell-derived macrophages in an intermediate (10-50 mL)-scale benchtop bioreactor. This Protocol can be implemented by users with basic iPS cell culture experience without requiring advanced bioprocessing expertise. This method consists of two primary endpoints: the generation of mesoderm-primed aggregates with hematopoietic potential, termed hemanoids, and the standardized production of iPS cell-derived macrophages that are ready for downstream applications. This Protocol enables continuous macrophage generation in long-term cultures, with a minimum of five consecutive collections, yielding an average of 2-3 × 107 cells per collection per vessel. Four vessels operate independently, each with a maximum culture volume of up to 50 mL, while critical process parameters (CO2, temperature and pH) are monitored. This semi-automated platform and in-process monitoring improve process control, leading to higher yields, reproducibility and cell quality compared with other systems. The simplified process spans 24 d, starting from single-cell iPS cells to ready-to-use macrophages. By bridging the gap between small- and large-scale systems, this approach provides scalable, standardized manufacturing of iPS cell-derived macrophages, making it a valuable tool for academics focused on human immune cells such as macrophages.
科研通智能强力驱动
Strongly Powered by AbleSci AI